Drug intelligence / Profile preview

TREG-AI-3

Development stage: Preclinical
Lead developer: TregTherapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

TREG-AI-3 is a preclinical-stage tolerogenic immunotherapy being developed by TregTherapeutics for the treatment of systemic autoimmune disease 3. The candidate is built on the company's proprietary TILAC (Tolerance Induction via Linked Adjuvant/Cytokine conjugate) platform, which was exclusively licensed from East Carolina University. TILAC is designed to shift the dendritic cell environment from immunogenic to tolerogenic signaling, thereby promoting the expansion of regulatory T cells (Tregs) to restore immune balance and attenuate disease-associated inflammation. TREG-AI-3 consists of an alum-based adjuvant conjugated with an anti-inflammatory cytokine.

Beyond the preview

Go deeper on TREG-AI-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TREG-AI-3.

Explore the full profile